Recent Posts
- Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu
- Chembio Diagnostics Appoints Industry Leader David Bespalko to its Board of Directors
- Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems
- Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors
- Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submission of the Rapid DPP SARS-CoV-2 Antigen Test System
Recent Comments